BioXcel Therapeutics to Present at the 2021 Jefferies London Healthcare Conference
11/11/2021 - 07:00 AM
NEW HAVEN, Conn., Nov. 11, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., Founder and Chief Executive Officer, and Frank Yocca, Ph.D., Chief Scientific Officer , will participate in a fireside chat at the 12th Annual Jefferies Global Healthcare Conference in London on Wednesday, November 17, 2021 at 4:20 p.m. GMT / 11:20 a.m. ET. Dr. Mehta and Dr. Yocca will highlight the Company’s neuroscience and immune-oncology programs, artificial intelligence platform used to augment and accelerate the drug candidate discovery and development process, and its commercial and launch readiness plans for BXCL501.
To access the live webcast of the presentation, please visit "News/Events" within the Investors & Media section of the Company’s website at www.bioxceltherapeutics.com . A replay of the webcast will be available on the Company’s website for 90 days following the event.
About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BioXcel Therapeutics’ two most advanced clinical development programs are BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation associated with psychiatric and neurological disorders, and BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. For more information, please visit www.bioxceltherapeutics.com .
Contact Information
Corporate
BioXcel Therapeutics Erik Kopp 1.203.494.7062ekopp@bioxceltherapeutics.com
Investor Relations
FTI Consulting Matt Ventimiglia 1.212.850.5624matthew.ventimiglia@fticonsulting.com
Media
FTI Consulting Helen O’Gorman 1.718.408.0800helen.ogorman@fticonsulting.com
Source: BioXcel Therapeutics, Inc.
BTAI Rankings
#5252 Ranked by Stock Gains
BTAI Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
New Haven
About BTAI
bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.